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Abstract  
Intra-abdominal dissemination of peritoneal nodules, a condition known as peritoneal carcinomatosis 
(PC), is typically diagnosed in ovarian cancer patients at the advanced stages. Current treatment of PC 
consists of perioperative systemic chemotherapy and cytoreductive surgery, followed by intra-
abdominal flushing with solutions of chemotherapeutics such as cisplatin and oxaliplatin. In this study, 
we developed cisplatin-loaded polyarginine-hyaluronic acid nanoscale particles (Cis-pARG-HA NPs) 
with  high colloidal stability, marked drug loading efficiency, unimpaired biological activity and tumor 
targeting ability. Injected Cis-pARG-HA NPs showed enhanced antitumor activity in a rat model of PC, 
when compared to injection of the free cisplatin drug. The activity of Cis-pARG-HA NPs could even be 
further improved when administered by an intra-abdominal aerosol therapy, referred to as pressurized 
intraperitoneal aerosol chemotherapy (PIPAC). PIPAC is hypothesized to ensure a more homogeneous 
drug distribution together with a deeper drug penetration into peritoneal tumor nodules within the 
abdominal cavity. Using fluorescent pARG-HA NPs, this enhanced nanoparticle deposit on tumors 
could indeed be observed in regions opposite the aerosolization nozzle. Therefore, this study 
demonstrates that nanoparticles carrying chemotherapeutics can be synergistically combined with the 
PIPAC technique for IP therapy of disseminated advanced ovarian tumors, while this synergistic effect 
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1.Introduction 
Ovarian cancer is one of the most commonly diagnosed cancers in women and is a leading cause of 
death among gynecological malignancies around the globe 1. The high mortality rate associated with 
ovarian cancer is largely by the fact that this cancer has proven refractory to most existing therapeutic 
modalities owing to its well-known metastatic behavior. At the advanced stages (stages III and IV), 
ovarian cancer is characterized by the formation of disseminated tumor nodules on the peritoneal 
membrane, a condition referred to as peritoneal carcinomatosis (PC) 2. Thus far, the standard of care for 
patients diagnosed with PC involves surgical removal of all macroscopic peritoneal metastases 
(cytoreductive surgery) together with perioperative and/or postoperative systemic intravenous (IV) 
chemotherapy with platinum and taxane-based compounds 3. The large surface area of the peritoneal 
cavity and poor vascularization of the peritoneum present, however, major obstacles to the effective 
eradication of PC via the current systemic chemotherapy regimens 4. Therefore, local intraperitoneal 
(IP) administration of chemotherapeutics was introduced around forty years ago, to provide a sufficient 
therapeutic concentration in the peritoneal cavity in order to enhance the local therapeutic effect while 
minimizing systemic adverse effects 5-7. Cytoreductive surgery (CRS), for example, is often combined 
with hyperthermic intraperitoneal chemotherapy (HIPEC), where the peritoneal cavity is flushed with a 
solution of chemotherapeutics at 38 - 42 °C for 30 minutes to several hours 8-9. However, only selected 
patients with PC are eligible for CRS along with HIPEC based on their tumor type and the extent of 
disease 10. For patients with unresectable tumors, a new minimally invasive, intra-abdominal aerosol-
based localized therapy has emerged, known as pressurized intraperitoneal aerosol chemotherapy 
(PIPAC) 4. In PIPAC, which is regarded as a palliative therapeutic option for patients suffering from 
PC, anticancer therapeutic agents are delivered into the closed and inflated peritoneal cavity as a 
pressurized normothermic aerosol, during a short laparoscopic procedure. It is speculated that the 
pressurized chemo-aerosols behave “gas-like”, ensuring a homogeneous drug distribution throughout 
the entire peritoneal space 4, 11-12. Furthermore, compared to conventional IP lavage, it appears that the 
generated artificial pressure gradient, in the shape of a 12 mmHg CO2 pneumoperitoneum, counteracts 
the elevated intra-tumoral interstitial fluid pressure, thereby enhancing the penetration of 
chemotherapeutic drugs into the peritoneal nodules 13. Nevertheless, the efficacy of localized IP 
chemotherapy is still hampered by pharmacological limitations such as rapid clearance of 
chemotherapeutics from the peritoneal cavity and minimal specificity towards cancer cells 14. Therefore, 
most patients develop disease recurrence in a short time after the local administration of 
chemotherapeutics.  
To prolong the residence time of chemotherapeutics in the peritoneal cavity, the encapsulation of 
chemotherapeutics into nanoparticles or controlled release systems is being evaluated. Furthermore, by 
applying surface modifications, nanoparticles could allow for optimal tumor targeting after 
administration in the peritoneal cavity15-17. A growing body of evidence has shown the potential of 
hyaluronic acid (HA), an anionic natural non-toxic mucoadhesive polysaccharide, for various 
biomedical and pharmaceutical applications (e.g., drug delivery, tissue engineering, cancer 
nanomedicine and molecular imaging) 18-20. In the area of cancer nanotherapy, there has been a special 
emphasis on the role of HA as a ligand for cluster determinant 44 (CD44) 21-22, which is considerably 
overexpressed on the surface of primary and metastatic peritoneal tumors 23. Therefore, the specific 
binding of HA to the CD44 receptors could lead to preferential internalization of nanoparticles into 
cancer cells 24-25. In addition, polyarginine (pARG), a cationic polyaminoacid, has been extensively 
utilized in drug delivery platforms due to its physicochemical and biopharmaceutical properties, 
biodegradability as well as good safety profile 26-27. In this study, we have developed a cross-linked  
nanoparticle system (NP) composed of  pARG and HA (pARG-HA NP) for the delivery of cisplatin, a 
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platinum-based anticancer drug. We first investigated the physicochemical properties of pARG-HA 
NPs, the cisplatin encapsulation efficiency and the in vitro release kinetics. Then, we explored the in 
vitro colloidal stability and biological activity of pARG-HA NPs in undiluted human biofluids, such as 
ascites and assessed the in vivo antitumor efficacy of cisplatin-loaded pARG-HA NPs (Cis-pARG-HA 
NPs) in a rat model of peritoneally disseminated human ovarian cancer, compared to free cisplatin. 
Given the limited amount of evidence considering the advantage of administering chemotherapeutics or 
nanoparticles as an aerosol, compared to injection into the peritoneal cavity as a solution, IP delivery 
was performed both by injection and nebulization, using the clinically applied PIPAC procedure. 
Finally, tumor accumulation and in-tissue penetration depth of IP nebulized and injected pARG-HA 
NPs were evaluated using fluorescence confocal microscopy. In summary, this study aimed to create 
insights into the pros and cons of the administration technique (liquid injection versus nebulization), and 
the added value of a nanoparticulate delivery platform for the delivery of cisplatin into the peritoneal 
cavity.   
 
2. Results and Discussion 
2.1. pARG and HA assemble into negatively charged nanoscale particles, displaying a long-term 
stability   
We developed a cross-linked nanoscale delivery vehicle consisting of two bioinspired and oppositely 
charged polymers, namely hyaluronic acid (HA) and polyarginine (pARG). Briefly, pARG-HA NPs 
were formed as a result of electrostatic complexation between HA and pARG at a concentration of 9 
mg/mL and 2.5 mg/mL (HA/pARG mass ratio: 4.5), respectively, at room temperature by the ionic 
gelation method 27-29. The positively charged primary amines of pARG interact with the negatively 
charged carboxylic groups of the HA backbone, leading to the formation of a spherical polymeric 
nanocarrier (Figure 1A). The developed nanoformulation featured an average hydrodynamic diameter 
of 249 ± 4 nm and a monodisperse size distribution (polydispersity index (PDI): 0.19 ± 0.02) in water 
as indicated by Dynamic Light Scattering (DLS) analysis. The deprotonated carboxyl groups in the HA 
polymer introduce a negative charge onto the surface of the NPs (zeta potential: -24 ± 1 mV) which is 
attributed to excess of HA relative to that of pARG in the formulation. Figure 1B depicts the stability 
profile of pARG-HA NPs over time. Evidently, pARG-HA NPs displayed a constant hydrodynamic 
diameter and surface charge in aqueous solution after isolation by centrifugation over the course of 84 
days when stored at 4 °C, suggesting a good physicochemical stability during long-term storage which 
is regarded as a crucial factor for adequate handling of the nanoformulations. In addition, it is inferred 
that the negatively charged surface of pARG-HA NPs may prevent the aggregation of nanoparticles 
through electrostatic repulsion and also provide long-term stability in aqueous solution. 
2.2. pARG-HA NPs efficiently encapsulate cisplatin and provide a sustained drug release over 8 
days 
Cisplatin is a potent platinum-based anticancer drug, approved as a chemotherapeutic agent in 1978  30 
31. Although it is now commonly used in medical oncology 32, the clinical implementation still suffers 
from intrinsic and acquired drug resistance and severe adverse effects, such as acute nephrotoxicity and 
chronic neurotoxicity 33-34. Encapsulation of platinum-based chemotherapeutic agents into nanoparticles 
can reduce off-target systemic toxicities and offer controlled drug release and protection of platinum 
drugs from degradation, thereby enhancing therapeutic efficacy 35-36. For polymers containing ionic 
blocks, cisplatin can be incorporated through coordination binding with the polyion blocks in an aqueous 
medium. For a polycarboxylate like HA, the carboxylic moieties have the ability to substitute the 
chloride groups (as the anionic ligands) in cisplatin, thereby forming a metal coordination bond between 
the platinum (Pt) II and the carboxyl group in HA polymers (Figure 1A). In turn, the presence of 
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abundant chloride ions can reverse this metal ion coordination bond, thereby regenerating free drug in 
chloride-rich environments 33, 37. To form a nanoparticle structure, the negatively charged HA can be 
mixed with positively charged pARG that acts as a cross-linking agent 27, 29.  
Guided by these principles, cisplatin-loaded pARG-HA NPs (Cis-pARG-HA NPs) were synthetized by 
mixing an aqueous cisplatin solution at a concentration of 1mg/mL with pARG and HA solutions at 
room temperature. To prevent the release of cisplatin by chloride ions, pARG-OH was used, obtained 
by hydroxylation of pARG-Cl. Cis-pARG-HA NPs displayed a slight decrease in size (213 ± 3 nm) 
compared to blank pARG-HA NPs, reflecting the formation of a more compact nanostructure in the 
presence of cisplatin 27, 29. Drug loading efficiency and encapsulation efficiency were determined to be 
8.1 ± 0.01 %  (w/w) and 74.7 ± 0.1% (w/w), respectively, as analyzed by inductively coupled plasma-
mass spectrometry (ICP-MS). The drug release kinetics of cisplatin from pARG-HA NPs exhibited two 
phases (Figure 1C). In the initial phase, an accelerated release profile was found with around 40% of 
total loaded cisplatin released from the nanosystem after 24 hours, followed by a sustained and slow 
release of drug over 8 days. This initial burst release may be ascribed to the release of cisplatin that is 
mainly complexed with the HA polymer on the surface of nanoparticles 38-39, while the sustained release 
of cisplatin might occur via an inverse ligand exchange reaction of the Pt (II) atom from the carboxyl 
group in the polymer chains to chloride in the chloride ion-rich solutions (for example, PBS and Saline) 
37, 40. In conclusion, HA-pARG NPs are expected to sustain the drug release of cisplatin upon IP 
administration 35. 
 
2.3. Free cisplatin and Cis-pARG-HA NPs exhibit comparable in vitro cytotoxicity 
Upon release of cisplatin from the nanoparticles in the cytosol, cisplatin undergoes an aquation reaction 
producing highly reactive species [Pt(NH3)2Cl(H2O)]+ or [Pt(NH3)2Cl(H2O)2]2+, which can enter the 
nucleus and bind to the N7 atoms of the purine residue guanine via coordination bonds, giving rise to 
the formation of intra-strand and inter-strand Pt-DNA cross-links. These DNA adducts interfere in 
cellular processing of DNA lesions, eventually inducing cell apoptosis 41-42. To explore the antitumor 
activity of released cisplatin from Cis-pARG-HA NPs, we first conducted in vitro efficacy studies 
(Figure 1D). About 99% of human ovarian cancer cells (SKOV-3) treated with drug-free nanoparticles, 
at equivalent polymer concentrations to Cis-pARG-HA NPs, remained viable for each of the examined 
concentrations, pointing to the fact that the polymeric constituents of pARG-HA NPs had no cytotoxic 
effects on the SKOV-3 cells as such. As shown in Figure 1D, the cytotoxicity was clearly enhanced in 
a dose-dependent manner for free cisplatin and Cis-pARG-HA NPs. The half-maximal inhibitory 
concentration (IC50) was determined as 28.9 ± 1.7 µM and 30.7 ± 3.6 µM for free cisplatin and Cis-
pARG-HA NPs, respectively, demonstrating the anticancer drug efficacy of cisplatin both in its free and 






















Figure 1: Preparation and characterization of pARG-HA NPs and Cis-pARG-HA NPs. (A) Schematic 
illustration of the development of pARG-HA NPs based on electrostatic complexation between 
negatively charged HA and positively charged pARG polymers. pARG-HA NPs can be loaded with 
cisplatin (Cis-pARG-HA NPs) (right) or fluorescently labeled using Alexa Fluor 647 (F-pARG-HA 
NPs) (left) by respectively adding cisplatin and Alexa Fluor 647 to the polymer solutions during 
synthesis. (B) Stability profile of pARG-HA NPs over time in aqueous solution in terms of size and 
surface charge. (C) Cumulative in vitro drug release kinetics of Cis-pARG-HA NPs over time in 
phosphate buffered saline (PBS) (pH: 7.4) at 37 °C. (D) Relative viability of human ovarian cancer cells 
(SKOV-3) following 24 h incubation with Cis-pARG-HA NPs, pARG-HA NPs and free cisplatin. All 
experiments were reproduced three times, each time in triplicate. Results are presented as mean ± SD 
and statistically significant differences between groups are shown as asterisks: *P < 0.05; ****P < 
0.0001; ns: nonsignificant analyzed by one-way or two-way ANOVA. 
 
2.4. pARG-HA NPs are colloidally stable in undiluted ascetic fluid  
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Colloidal stability is a decisive factor for the success of any nano-sized delivery system upon exposure 
to physiological conditions within the human body. When a nanoscale system encounters biological 
environments, various proteins abundant in extracellular fluids can rapidly adsorb onto the NP and cover 
its surface. This so-called ‘protein corona’ might highly affect the nanoparticle physicochemical 
properties (e.g., size, charge and surface features), its stability (e.g., aggregation or premature cargo 
release) and biological activity (e.g., cellular uptake, intracellular trafficking, biodistribution, toxicity 
and clearance patterns) 43-44. Although DLS is the most common technique to determine the size 
distribution profile of small-sized particles in aqueous media, it should be noted that it typically fails to 
precisely characterize the NP size in undiluted biological fluids, primarily owing to strong light 
scattering by the proteins in theses biofluids. We have previously shown, however, that fluorescent 
Single Particle Tracking (fSPT) is able to examine the colloidal stability of nanoparticle formulations in 
undiluted biofluids (e.g., ascites, serum, blood and plasma) on a per particle basis 45. Therefore, we 
investigated the colloidal stability of the pARG-HA NPs in ascetic fluid, as a relevant physiological in 
vitro condition for intraperitoneal administration by fluorescent Single Particle Tracking (fSPT) 45. 
Fluorescently labeled pARG-HA NP (F-pARG-HA NP) were prepared by the electrostatic 
encapsulation of Alexa Fluor 647 carboxylic acid, tris (triethylammonium) salt (Figure 1A), resulting in 
NPs with similar physicochemical characteristics as compared to unlabeled ones (250 ± 10 nm and -
23.5 ± 1.1 mV). As shown in Figure 2A, the NP size measured with fSPT in distilled water was in line 
with our DLS results, with a peak diameter around 265 nm. Incubation of F-pARG-HA NPs in 90% vol. 
ascetic fluid was accompanied by an increase in size from approximately 250 nm to 466 nm at 1 h post-
incubation at 37 °C, showing a slight nanoparticle aggregation in ascetic fluid. Of note, it has been 
recently reported that formation of an ascites-induced protein corona and the subsequent NP size 
expansion could inhibit undesired drainage through lymphatic duct openings and thus lengthen 
peritoneal retention 46,47. Furthermore, only a small fraction of ascites may exist in the peritoneal cavity 
of patients eligible for CRS and adjuvant IP chemotherapy regimens, considering that all ascetic fluid is 
drained off the peritoneal space before any IP surgical or chemotherapeutic procedure is pursued. This 
can in part minimize the protein-nanoparticle interactions in ascites, when nano-sized delivery vehicles 
are administered to the peritoneal cavity of patients with PC. Taken together, we found a slight 
aggregation of F-pARG-HA NPs in ascetic fluid, which possibly results from the formation of a protein 
corona on the NPs surface. In the next section, we investigated whether this protein corona also 
influences the cellular uptake of the F-pARG-HA NPs.   
 
2.5. pARG-HA NPs are internalized into SKOV-3 cells through CD44-receptor mediated 
endocytosis 
In the next set of experiments, we explored whether F-pARG-HA NPs can be efficiently internalized 
into SKOV-3 cells and whether or not internalization was influenced by 1 hour pre-incubation in 90% 
vol. undiluted biofluids such as human serum and ascites. Therefore, F-pARG-HA NPs were incubated 
in the biological fluids at 37 °C for 1 hour and NP uptake was subsequently assessed using flow 
cytometry. Our results confirmed high cellular uptake of F-pARG-HA NPs in Opti-MEM (i.e., low-
protein content), as well as after pre-incubation in human serum and ascites (i.e., high protein 
concentration), with more than 86% of the cell population internalizing NPs within the 4 hours of 
exposure (Figure 2B).  The high cell-associated fluorescence intensity for all the examined conditions 
(i.e., Opti-MEM, serum and ascites) demonstrates that cellular uptake is unaffected in protein-rich 
conditions. Hence, the protein corona formed around the nanoparticles in biological fluids, if any, did 
not interfere with the uptake of the NPs by the SKOV-3 cells. Possibly, the negatively charged surface 
of pARG-HA NPs, protects the nanocarriers not only against aggregation but also limits the interaction 
between NPs and anionic charged proteins abundant in biological fluids. 
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Possibly, HA on the NP surface could act as a targeting ligand that enables the specific uptake by CD44-
overexpressing tumor cells like SKOV-3 cells 24-25, 35, 48-50. To verify this hypothesis, the cellular uptake 
behavior of F-pARG-HA NPs was studied in SKOV-3 cells in the absence or presence of high 
concentration of free HA (10 mg/mL). Pre-exposure of SKOV-3 cells with excess free HA led to a clear 
decrease in percentage of positive cells as well as fluorescence intensity that may be indicative of 
blockage of CD44 receptors by free HA (Figure 2C). In the absence of free HA, by contrast, our results 
revealed that NPs were significantly taken up by the cells, possibly denoting the specific HA-CD44 
interactions, facilitating NP cellular internalization (Figure 2C). The successful uptake of F-pARG-HA 
NPs by SKOV-3 cells through CD44-receptor mediated endocytosis was further confirmed by confocal 
microscopy, where the high intracellular accumulation of F-pARG-HA NPs was evident from a strong 
red signal in the cytoplasm (Figure 2D). Conversely, a low level of intracellular fluorescence was 
monitored (a weak red signal) in the cytosol of free HA-treated SKOV-3 cells, again confirming that 
saturation of the CD44 receptors with free HA to a great extent diminished the cellular internalization. 
Therefore, both flow cytometry and confocal microscopy confirm that F-pARG-HA most likely entered 
the SKOV-3 cells in a target-specific manner via strong binding affinity of HA to the CD44 receptor. 
To further confirm that F-pARG-HA NPs uptake proceeds through the CD44 receptor, competitive 
inhibition study was performed with an additional cell line. Therefore, the 3T3 (mouse fibroblast) cell 
line was used, that does not express high levels of CD44 receptors, when compared to SKOV-3 cells. 
Our results  demonstrate low mean fluorescence intensity in 3T3 cells, indicating low cellular uptake of 
F-NPs by 3T3 cells both in the presence and absence of free excess HA. In SKOV-3 cells, however, a 
high mean fluorescence intensity (reflecting high cellular uptake) is observed, that decreases in the 
presence of high concentration of free HA. This in turn denotes the CD44 mediated uptake of pARG-









Figure 2.  (A) In vitro colloidal stability of pARG-HA NPs in the presence of biofluids. Snapshots and 
size distribution profile of pARG-HA NPs following 1h incubation in distilled water and 90% vol. 
undiluted human ascites at 37 °C, obtained by fSPT analysis. In the fSPT size distributions, Y-axis 
points to the frequency (f) of nano-sized particles observed with the corresponding size on the X-axis. 
(B) In vitro uptake of pARG-HA NPs by SKOV-3 cells in Opti-MEM (i.e., low-protein content), as well 
as 90% vol. undiluted human serum and ascites (i.e., protein-rich condition) 4 h after exposure. The 
cellular uptake behavior of pARG-HA NPs was quantified based on percentage of positive cells and 
mean fluorescence signal intensity in all examined conditions. (C) In vitro cellular internalization of 
pARG-HA NPs through CD44-receptor mediated endocytosis in the presence or absence of excess free 
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HA, assessed by flow cytometry analysis and (D) confocal microscopy (blue: nucleus, red: F-pARG-
HA NPs). All experiments were reproduced three times, each time in triplicate. Results are presented as 
mean ± SD and statistically significant differences between groups are shown as asterisks: ****P < 
0.0001; ns: nonsignificant analyzed by one-way or two-way ANOVA. 
 
2.6. Aerosolization of Cis-pARG-HA NPs synergistically results in a pronounced antitumor 
efficacy in a rat model of peritoneal metastasis  
Locoregional intraperitoneal chemotherapy has the potential to concentrate anticancer therapeutics at 
the tumor site, resulting in enhanced local antitumor responses and minimized systemic adverse effects 
6, 51. In the pursuit of developing new IP drug delivery strategies for PC therapy, a minimally invasive, 
intra-abdominal aerosol-based therapy, referred to as PIPAC, has been recently introduced 11. By 
harnessing the physical properties of gas and pressure, PIPAC delivers cytotoxic agents in the form of 
a pressurized aerosol to the peritoneal space, thereby warranting a more homogeneous drug distribution 
and a deeper drug penetration into peritoneal tumor nodules within the abdominal cavity 52-53. Also 
nanotechnology-based drug delivery systems present several prominent features for locoregional drug 
delivery, such as extended peritoneal retention and targeted drug delivery towards the desired tumor 
tissue 15-16. Thus far, however, only a very few studies have been devoted to examine the in vivo 
feasibility and therapeutic benefits of IP aerosolization of nanoparticle-based cancer therapeutics 54 55. 
Therefore, the feasibility and added benefits of the PIPAC therapy with nanoparticles still largely remain 
to be elucidated.   
In this study, we explored the in vivo potency of cisplatin-loaded pARG-HA NPs in a rat model of 
intraperitoneally disseminated human ovarian cancer 56-57, with a special focus on the potential 
advantage of formulating cisplatin into a nanoparticle system and whether or not liquid aerosolization 
is beneficial compared to liquid injection of NPs into the peritoneal cavity. Tumor-bearing rats were 
dosed either with free cisplatin (5 mg/kg) or cisplatin-loaded pARG-HA NPs (at 5 mg/kg dose-
equivalent level of Pt) through a single injection or nebulization (PIPAC) (Figure 3A). In the control 
group, rats were IP injected with saline (0.9% NaCl) alone. The rat is a well-suited animal model for the 
PIPAC procedure 54, 57, as the adequate space of the peritoneal cavity allows PIPAC to be effectively 
performed in clinically relevant conditions. Figure 3B illustrates the surgical procedure of the PIPAC 
method in a rat model of peritoneal surface malignancies, which was conducted during laparoscopy. 
The nebulization was monitored with a camera, to confirm the formation of an aerosol within the closed 
space of the peritoneal cavity.  
Upon IP delivery of free cisplatin or Cis-pARG-HA NPs, tumor growth and progression of metastasis 
were continuously monitored utilizing serial bioluminescence imaging for 3 weeks post-treatment 
(Figure 3C and Figure S2). Furthermore, the average tumor weight (Figure 3E) and spread of metastasis 
in the peritoneal cavity (Figure 3F) was determined, together with the overall survival of animals in the 
different treatment groups (Figure 3G). Control animals (treated with saline), showed an aggressive 
tumor growth, leading to a rapid spread of tumor nodules over the entire peritoneal membrane within 8 
days, along with a dramatic increase in the corresponding average radiance value of tumors (Figure 3D, 
green line). Consequently, all animals had a high tumor weight (Figure 3E, green dots) and reached the 
humane endpoint at maximum 8 days following treatment (Figure 3G, green line). Animals that were 
treated with free cisplatin, either through IP injection (dark blue line) or nebulization (light blue line), 
exhibited a minimal reduction in their tumor burdens 4 to 8 days post-administration, as compared to 
those receiving saline alone. Although there seems to be a small delay in tumor growth, as evidenced 
by Figure 3D and 3E, animals again reached the humane endpoint by maximally day 15 post treatment 
(Figure 3G, dark and light blue lines). Therefore, it appears that a single IP administration of cisplatin 
is only able to reduce the tumor growth rate for a short period of time, and peritoneal tumors are prone 
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to rapid relapse immediately after cisplatin is cleared from the peritoneal cavity and absorbed into the 
systemic circulation (due to its small molecular size). Interestingly, for the group receiving IP injected 
Cis-pARG-HA NPs, tumor progression was remarkably delayed for the first 8 days following treatment, 
in contrast to free cisplatin (Figure 3D, purple line compared to dark and light blue line) and saline 
groups (Figure 3D, green line). Although the tumor growth resumed by the 14th day post-injection, the 
maximal average radiance of tumors was much lower than those of rats injected with free cisplatin or 
saline. Therefore, it seems that encapsulating the cisplatin into pARG-HA NPs can lengthen the 
residence time in the peritoneal cavity and simultaneously provide sustained drug release to the tumor 
site, corresponding to the sustained release of cisplatin from pARG-HA NPs over 8 days as found in the 
in vitro release study (Figure 1C). More intriguingly, the good anti-tumor efficacy even further improved 
when Cis-pARG-HA NPs were nebulized in the peritoneal cavity of the tumor bearing rats. Indeed, a 
nearly complete inhibition of tumor regrowth was observed within 21 days post-treatment, 
demonstrating a synergistic anticancer effect of the combinatorial application of cisplatin-loaded 
nanoparticles and the PIPAC technique (Figure 3D, orange line). The superior anti-tumor activity of cis-
pARG-HA NPs both after injection and (even more) nebulization is also evident from the weight of 
intra-abdominal nodules. As shown in Figure 3E, the average tumor weight of rats treated with saline, 
IP injected cisplatin and IP nebulized cisplatin was found to be 5.5 ± 0.9g, 4.2 ± 0.9g and 3.4 ± 0.5 g 
per rat, respectively, resulting in no statistically significant difference between these 3 treatment groups. 
Both injected and nebulized Cis-pARG-HA NPs, however, exhibited a notable decrease in the average 
weight of total tumor nodules isolated from the peritoneal cavity, with 1.2 ± 1.1g and 0.07 ± 0.06g per 
rat for IP injection and nebulization, respectively (Figure 3E). Moreover, the extent of tumor 
dissemination in the peritoneal cavity of animals sacrificed at their humane endpoint confirmed the 
superior activity of nebulized Cis-pARG-HA NPs (Figure 3F). In the saline and IP injected/nebulized 
cisplatin groups, numerous metastatic nodules were found all over the intestine and mesentery (Figure 
3F, closed black lines). IP injection of Cis-pARG-HA NPs, retarded the spread of tumor nodules on the 
peritoneum, as only a few small disseminated nodules remained, whereas nebulization of Cis-pARG-
HA NPs even led to no or nearly undetectable levels of tumor nodules in the peritoneal cavity (Figure 
3F). Collectively, our results indicate that Cis-pARG-HA NPs are highly effective in delivering cisplatin 
to tumors in the peritoneal cavity and can withstand the forces and high pressure generated during the 
aerosolization procedure (as confirmed by their in vitro colloidal stability upon nebulization (Figure 





















Figure 3. In vivo antitumor efficacy of cisplatin-loaded pARG-HA NPs in a rat model of intaperitoneally 
disseminated human ovarian cancer upon IP injection and IP nebulization (PIPAC). (A) Treatment 
schedule adopted in this study. (B) Schematic illustration of surgical procedure of the PIPAC method in 
a tumor bearing rat, performed during a short laparoscopic procedure. Video monitoring is provided by 
a 5 mm camera (laparoscope), confirming the formation of aerosol particles within the closed space of 
the peritoneal cavity. CAWS, closed aerosol waste system. (C) The antitumor activity of different IP 
therapeutic strategies according to whole-body bioluminescence images of animals in each treatment 
group. The most representative animal in each group is presented (the complete overview of animals 
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can be found in Figure S2). Tumor growth and progression of metastasis were continuously monitored 
utilizing serial bioluminescence imaging for 3 weeks post-treatment. (D) Tumor growth profile of each 
treatment group over time, as determined according to changes from baseline average radiant flux 
associated with the bioluminescence signal intensity. (E) Weight of intra-abdominal tumor nodules per 
rat. (F) Representative photographs of extent of tumor dissemination in the peritoneal cavity of animals 
that reached the humane endpoint (on average, 8, 14 and 21 days post-IP administration for saline/free 
cisplatin, injected Cis-pARG-HA NPs and nebulized Cis-pARG-HA NPs respectively) . The closed 
black lines indicate the area that metastatic peritoneal nodules are located. (G) Overall survival curves 
of the tumor bearing rats in each treatment group. All experiments were reproduced three times. Results 
are presented as mean ± SD (n=3-4) and statistically significant differences between groups are shown 
as asterisks: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001  analyzed by one-way or two-way 
ANOVA.  
 
2.7. PIPAC may improve the in vivo accumulation and penetration of pARG-HA NPs into 
peritoneal tumor nodules 
To gain a better insight into the mechanism underlying the in vivo potency of the Cis-pARG-HA NPs, 
fluorescently labeled pARG-HA NPs were intraperitoneally injected or nebulized in tumor baring rats 
and biodistribution and tumor penetration was assessed 48 hours after IP administration. The 
homogeneity of the distribution of NPs was evaluated by harvesting tumor nodules from different 
regions of the peritoneal cavity as illustrated in Figure 4A. IP aerosolized pARG-HA NPs more 
effectively accumulated at the edge of the peritoneal nodules located in the regions directly opposite and 
around the MIP® nozzle (nodules c and d, with fluorescence intensities between 200 and 250 a.u.), while 
nodules a and b, located more distant from the aerosol jet displayed a lower overall fluorescence intensity 
(between 100 and 150 a.u.) (Figure 4A). With regard to NPs delivered via IP injection, both tumor 
nodules harvested from random locations in the peritoneal space (namely region e and f), showed 
identical results regarding tumor accumulation and fluorescence signal intensity of pARG-HA NPs 
(with average fluorescence intensities between 100 and 150 a.u). Our findings are consistent with 
previous studies indicating that the intra-abdominal drug distribution after PIPAC is not as homogeneous 
as expected but varies between different regions of the peritoneal cavity 58. As validated by 
granulometric analysis, about 97.5 vol. % of the aerosol droplets delivered by the PIPAC micropump 
are not submicronic (size range between 3-200 µm) and consequently do not have the ideal physical 
properties to distribute homogenously. As a result, such aerosol droplets are primarily deposited in the 
areas on the opposite side of the MIP® nozzle outlet because of gravitational settling and inertial 
impaction, thereby forming local “hotspots” on the peritoneum beneath the MIP® and in areas lateral to 
the aerosol jet 59-62. The same holds true for in-tissue drug penetration depth provided by PIPAC, where 
a deeper penetration of aerosolized drugs into the tissue (>311 µm in depth) was observed in the local 
hotspots created on the peritoneum in the vicinity of  the MIP® 61-63. Also, we observed that the majority 
of IP-nebulized NPs were largely localized at the edge of the tumor tissue opposite the nebulizer with a 
maximum penetration depth of approximately 200-300 µm. This penetration depth might be sufficient, 
however, to prevent cancer recurrence, as most tumor nodules that remain in the peritoneal cavity after 
cytoreductive surgery are microscopic tumors nodules.  
Quantitative analysis of the fluorescence signal intensity emanating from F-pARG-HA NPs in the tumor 
tissue sections revealed that, on average, identical fluorescent signals were obtained in the IP cavity of 
rats receiving pARG-HA NPs through injection or nebulization (Figure 4B, light green bars). The 
maximum fluorescence intensity that was observed in tissue sections, however, was always higher for 
IP nebulization, in comparison to IP injection (Figure 4B, dark green bars). This confirms that IP 
aerosolized delivery of pARG-HA NPs overall deposits higher nanoparticle concentrations on the tumor 
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nodules, when compared to IP injection, resulting in the formation of more highly intense NP hotspots.  
Of note, a low background signal was detected in the control tissues such as liver, spleen and kidney 
(Figure 4C), indicating that pARG-HA NPs preferentially homed to tumor nodules and were not readily 
cleared from the peritoneal cavity and subsequently trafficked into filtering organs (e.g., spleen and 
liver). This biodistribution was also confirmed using a rat model with one big tumor nodule, instead of 
numerous small peritoneal tumor nodules (Figure S4). As supported by our data on in vitro cellular 
uptake, it is likely that the preferential accumulation of pARG-HA NPs in the tumor tissue stems from 
the CD44-receptor targeting ability of NPs conferred by HA exposed on the NP surface as a targeting 
ligand. Collectively, intraperitoneally administered pARG-HA NPs revealed tumor targeting ability, 






















Figure 4.  Tissue biodistribution and tumor penetration of intraperitoneally nebulized and injected 
fluorescently labeled pARG-HA NPs in the female nude rats bearing IP disseminated tumors, 48 hours 
after IP administration. (A) Representative fluorescence confocal images and corresponding fluorescent 
intensity distributions of tumor tissue sections excised from different locations in the peritoneal cavity 
with respect to proximity to the nebulizer (Micropump-MIP®) outlet (regions c and d), or distant from 
the created aerosol jet (regions a and b) in the PIPAC method, as well as random locations in the 
peritoneal space (regions e and f) for IP injection. (B) Quantification of the fluorescence signal intensity 
of F-pARG-HA NPs in tissue sections of peritoneal nodules following IP nebulization and injection. 
The fluorescence signal intensity is expressed as an average and maximum signal intensity per tumor 
nodule. (C) representative confocal images of tissue sections of control organs (i.e., kidney, liver and 
spleen) harvested upon IP nebulization and injection of F-pARG-HA NPs along with IP injection of 
saline as a control. All experiments were reproduced three times (n=3-4). 
  
3. Conclusions 
Our study offers a starting point for the combinatorial application of cancer nanotherapies and the 
PIPAC procedure by presenting the therapeutic benefits of IP aerosolization of cisplatin-loaded pARG-
HA NPs in a rat model of IP disseminated human ovarian cancer. pARG-HA NPs were efficiently loaded 
with cisplatin, demonstrated colloidal stability in ascetic fluid and internalized into SKOV-3 cells 
through CD44 targeting mediated by the HA surface of the nanoparticles. Furthermore, cisplatin-loaded 
nanoparticles showed an enhanced antitumor activity in a rat model of peritoneal carcinomatosis when 
compared to the injection or nebulization of free cisplatin. The therapeutic potential was even further 
enhanced by the nebulization of pARG-HA NPs into the peritoneal cavity, demonstrating the synergistic 
effect of nebulization and encapsulation of cisplatin into a nanoparticle system. The sustained release of 
cisplatin from the pARG-HA NPs, together with the preferential accumulation of pARG-HA NPs in the 
metastatic tumor nodules opposite the nebulizer nozzle, most likely contribute to the observed 
synergistic effect. Overall, our results suggest the potential advantages of IP aerosolization of pARG-
HA NPs over injection, although there is still significant room for improvement of the delivery of cancer 
nanotherapeutics via the PIPAC technique to achieve a more homogeneous tissue distribution and 
enhanced penetration depth. For example, the recent development of new PIPAC methods such as 
hyperthermic intracavitary nanoaerosol therapy (HINAT) 64 and electrostatic PIPAC (ePIPAC) 65 might 
yield a more uniform intra-abdominal drug distribution pattern and a deeper penetration of drug into the 
tissue, compared to the conventional PIPAC method. In addition, future studies are needed to understand 
whether or not repetition of the PIPAC therapy itself or in combination with other controlled release 
delivery platforms (for example, in-situ cross-linkable hydrogels) is feasible to maintain the therapeutic 
concentration of Cis-pARG-HA NPs within the peritoneal space over prolonged periods of time. 
 
4.Materials and Methods 
4.1 Materials 
Cisplatin (cis-diamminedichloroplatinum (II)) was purchased from Abcam (Cambridge, UK). Poly-L-
Arginine (PA) hydrochloride (Mw = 5800 Da) was purchased from Alamanda® Polymers (Huntsville, 
Alabama, USA). Hyaluronic acid (HA) (Mw = 20 kDa) was purchased from Lifecore® Biomedical 
(Chaska, Minnesota, USA). McCoy’s 5A modified medium, Fetal Bovine Serum (FBS), penicillin-
streptomycin (5000 U/ml), 0.25% Trypsin-EDTA (1×), Dulbeco Phosphate buffered Saline (DPBS), 
Opti-MEM, Alexa Fluor 647 carboxylic acid, TRIS (triethylammonium) salt and Hoechst 33342 were 
purchased from Invitrogen (Merelbeke, Belgium). 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
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tetrazolium bromide (MTT) and Paraformaldehyde (PFA) were purchased Sigma Aldrich® (St. Louis, 
Missouri, USA). 0.9% Sodium Chloride (NaCl) was purchased from B. Braun (Melsungen, Germany).  
 
4.2 Animals 
All animal studies were conducted under approved protocols by the Animal Ethics Committee of the 
Faculty of Medicine and Health Sciences, Ghent University, Belgium (ECD 18/23), and in compliance 
with the Belgian Council for Laboratory Animal Science (BCLAS) guidelines for the Care and Use of 
Laboratory Animals. Athymic female nude rats (Foxn1: nu/+) (8-10 weeks, ≥ 200 g) were purchased 
from Envigo (Horst, the Netherlands) and housed in the animal core facility. All animals were 
maintained under controlled conditions with a 12h h light/dark schedule and food and water ad libitum 
and acclimatized to standard housing conditions for at least one week prior to experiments. 
 
4.3 Development and characterizations of blank, fluorescently labeled and cisplatin-loaded Par-
HA NPs 
pARG-HA nanosystems composed of hyaluronic acid (HA) and polyarginine hydroxide (pARG-OH) 
were synthetized via the ionic gelation method (HA/pARG mass ratio: 4.5) 27-28. pARG-OH was 
obtained from polyarginine chloride (pARG-Cl) using an Amberlite® IRA 900 Cl ion exchange resin 
(Sigma Aldrich®, St. Louis, MO, USA). To prepare the pARG-OH, NaOH (1M, 3 mL) was added to an 
ion exchange column containing 1 mL of wet resin. After 30 minutes, the column was rinsed with MilliQ 
water to adjust the pH to 7 and the pARG-Cl solution (50 mg/mL, 1 mL) was subsequently added to the 
column, followed by rinsing the column with 3mL of MilliQ water. Finally, the pARG-OH at the 
concentration of 12.5 mg/mL (pH: 10-12) was obtained and stock solution was stored at 4 °C afterwards. 
Prior to preparation of nano-sized systems, all solutions were filtered through a 0.22 µm filter. To 
synthetize the blank pARG-HA NPs, briefly, 80 µl of pARG-OH solution (2.5 mg/ml) and 120 µl of 
distilled water were mixed in a glass amber vial by magnetic stirrer. Then, 100 µl of HA solution 
(9mg/ml) was added to the middle of vortex and the dispersion was kept under magnetic stirring for 10 
minutes. Cis-pARG-HA and F-pARG-HA NPs were developed with the same method as described for 
blank NPs, but instead of distilled water, 120 µL of cisplatin solution (1 mg/mL) or Alexa Fluor 647 
carboxylic acid, tris (triethylammonium) salt (0.8 mg/ml) (Invitrogen, Merelbeke, Belgium) were added 
to the pARG-OH solution for development of cisplatin-loaded and fluorescently labeled nanoparticles, 
respectively. Upon completion of NP synthesis, all prepared mixtures were subjected to centrifugal 
separation to ensure the removal of non-complexed constituents such as free cisplatin, Alexa fluor 647, 
pARG-OH and HA polymers. To isolate the developed nanoparticle formulations, 300 µl of the 
nanocarrier dispersion was transferred to an Eppendorf microtube containing 20 µl of glycerol and 
centrifuged at 16000 g for 30 minutes at 25°C. Next, the supernatant was discarded and the pellet was 
resuspended in distilled water through vigorous vortexing. The nanoformulations were stored at 4°C 
afterwards. All nanoformulations were further diluted in distilled water to a final volume of 1000 µL 
and size and zeta potential were subsequently measured by Zetasizer Nano-ZS (Malvern, 
Worcestershire, UK). Following encapsulation of cisplatin in pARG-HA NPs drug loading content and 
encapsulation efficiency were analyzed by ICP-MS and calculated according to the equations as follows: 
Drug Content (%) = 
Weight of cisplatin in nanoparticles
weight  of polymers fed initially
 × 100 
Encapsulation Efficiency (%) = 
Weight of cisplatin in nanoparticles
weight  of cisplatin fed initially
 × 100 
4.4 In vitro release kinetics  
1 mL of Cis-pARG-HA NPs dispersion (0.36 mg Pt) was placed in a Float-A-Lyzer®G2 dialysis tube 
(MWCO: 3.5-5 kDa) (Spectrum Laboratories, California, USA) and immersed in 75 mL of PBS (pH: 
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7.4), stirring constantly at 37 °C for 1 week. At given time points, samples (1mL) were collected from 
the release medium and replaced with fresh PBS. Pt content was determined using ICP-MS afterwards.  
 
4.5 Collection of biological fluids 
To obtain the human serum, blood was withdrawn from healthy volunteers and collected into 
VenosafeTM tubes (6 mL) containing gel and clotting activator (Terumo EuropeTM, Leuven, Belgium) 
at Ghent University Hospital. Thereafter, the tubes were centrifuged (4000 g, 10 min, 20 °C) and serum 
(supernatant) was transferred into microvette® 500 Z-Gel (SARSTEDT, Numbrecht, Germany) and 
subjected to centrifugation (10000 g, 5 min, 20 °C). The obtained serum was then stored at -20 °C. 
Furthermore, human ascites was obtained from patients with peritoneal carcinomatosis at the department 
of medical oncology, Ghent University Hospital, according to an approved procedure by the ethics 
committee of the Ghent University Hospital (EC no. 2013/589). 
 
4.6 In vitro colloidal stability of pARG-HA NPs in biological fluids  
Fluorescent Single Particle Tracking, a well-suited advanced fluorescence microscopy technique, 
enables us to precisely examine the colloidal stability of nano-sized delivery systems in undiluted 
biological fluids (e.g., ascites, serum, blood and plasma) on a per particle basis, as shown previously 66. 
In short, fSPT exploits an iXon ultra EMCCD camera (Andor Technology, Belfast, UK) and a swept-
field confocal (SFC) microscope (Nikon eclipse Ti, Japan) equipped with an MLC 400 B laser (Agilent 
technologies, California, USA) to record high-speed movies of individual fluorescently labeled particles 
diffusing in biofluids. Captured videos are then analyzed by in-house image processing software, 
obtaining a distribution of diffusion coefficients which is then converted into a size distribution utilizing 
the Stokes-Einstein equation, considering the viscosity of biofluids and temperature at which the 
experiment is conducted. To perform fSPT measurements on F-pARG-HA NPs dispersed in 90% vol. 
biological fluids, nanoparticle formulations were first diluted 15 times in distilled water and 5 µl of the 
prepared dilutions was then added to 45 µl of distilled water or biofluids (e.g., human serum and ascites) 
and incubated for 1 hour at 37°C. Afterwards, 7µl of each sample was mounted on a microscope slide 
in the middle of a secure-seal adhesive spacer (8 wells, 9 mm diameter, 0.12 mm deep, Invitrogen, 
Merelbeke, Belgium) and the slide was covered by a cover slip (24 × 50 mm) in order to avoid sample 
evaporation and to afford free NP diffusion during fSPT measurements. The slide was then placed on 
the swept field confocal microscope and movies were recorded focused at ~5 μm above the bottom of 
the microscope slide. The fSPT videos of different nanoformulations were recorded at room temperature 
(22.5 °C) with the NIS Elements software (Nikon, Japan) driving the EMCCD camera and a  swept-
field confocal microscope equipped with a CFI Plan Apo VC 100× NA 1.4 oil immersion objective lens 
(Nikon, Japan). Thereafter, videos were analyzed using in-house developed software, as explained 
previously 45-46.  
 
4.7 Cell culture 
The human ovarian cancer cell line SKOV-3 was used for in vitro experiments. Cells were cultured in 
McCoy’s 5A medium supplemented with 10% Fetal Bovine Serum (FBS) and penicillin/streptomycin, 
and maintained in an incubator at 37 °C, in a humidified atmosphere with 5% CO2. Cells were cultured 
until the 80-90 % confluency and then detached using 0.25% trypsin/EDTA.   
 
4.8 Cell viability assay  
SKOV-3 cells were seeded in a 24-well plate at a density of 50,000 cells/well and then cultivated at 37 
°C. After 24 h, cells were incubated with Cis-pARG-NPs or free cisplatin at a final platinum (Pt) 
concentration ranging from 1-100 µM in each well containing Opti-MEM (final volume 500 µL). Cells 
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in the control group were treated with blank pARG-HA NPs at equivalent polymer concentrations to 
Cis-pARG-HA NPs. Cells were then incubated with all nanoparticle formulations for 24 h at 37 °C, with 
5% CO2. At the end of treatments, cell viability was determined by MTT assay. Cells were rinsed with 
PBS and 100 µL of MTT solution (5 mg/mL MTT in PBS) was added to each well containing 400 µL 
of McCoy’s 5A and incubated for 3 h at 37 °C. Afterwards, 500 µL of DMSO was added to each well 
to solubilize formazan crystals. The plate was then covered with aluminum foil and place on the orbital 
shaker for 30 min at 100 rpm. The absorbance of solubilized formazan was determined with a Wallac 
Envision TM multilabel reader (PerkinElmer, Zaventem, Belgium) at 590 nm wavelength with reference 
at 690 nm. The measured absorbance was normalized to that of cells treated with Opti-MEM alone.    
 
4.9 In vitro cellular uptake of pARG-HA NPs in the presence of biofluids 
SKOV-3 cells were seeded in a 24-well plate (50,000 cells/well) and allowed to grow in an incubator at 
37 °C for 24 h. For uptake studies in biofluids, F-pARG-HA NPs were pre-incubated in Opti-MEM, 
human serum or ascetic fluid (90% vol. of biological fluids) for 1h at 37 °C. Following pre-incubation 
in aforementioned media, F-pARG-HA NPs were added to each well (3.2 × 106 nanoparticles/well) 
containing Opti-MEM (final volume: 500 µL) and incubated for 4 h 37 °C. At the end of the incubation 
time, cells were washed twice with DPBS [-], trypsinized and analyzed using flow cytometry (FACS 
Calibur Flow Cytometer, BD Bioscience, USA).  
 
4.10 Competitive inhibition study 
SKOV-3 cells were seeded in a 24-well plate at the density of 50,000 cells/well and allowed to grow for 
24 h at 37 °C. F-pARG-HA NPs, dispersed in serum-free medium, were added to each well (3.2 × 106 
nanoparticles/well) containing Opti-MEM (final volume: 500 µL), with or without HA (10 mg/mL). 4 
h post-exposure of the cells to NPs, the cells were washed twice with PBS, detached using trypsin/EDTA 
and cellular uptake was analyzed by Cytoflex (Beckman Coulter, Suarlée, Belgium). For confocal 
microscopy, SKOV-3 cells (150,000 cells/dish) were plated in a 35 mm glass-bottomed petri dish 
(Greiner Bio-One, Frickenhausen, Germany) and incubated for 24 h at 37 °C. Thereafter, cells were 
incubated with F-pARG-HA NPs suspended in Opti-MEM (9.6 × 106 nanoparticles/dish), either with or 
without HA (10 mg/mL). 4 h upon incubation, cells were washed twice with PBS, fixed with 
paraformaldehyde (PFA) (4% in PBS), and cell nuclei were stained with Hoechst 33342 (1 µg/mL). 
Cellular uptake was subsequently analyzed using confocal microscopy (C2 Nikon). 
 
4.11 In vivo therapeutic efficacy of Cis-pARG-HA NPs 
To establish a rat model of IP disseminated human ovarian cancer, 18 × 106 SKOV-3 Luc IP2 cells, 
suspended in 5 mL DPBS [-], were IP injected into athymic female nude rats (8-10 week old, ≥ 200 g). 
Tumor growth was monitored using an IVIS Lumina II whole body imaging system (PerkinElmer, 
Zaventem, Belgium) until the bioluminescence signal reached 1 × 108 radians (photons/sec/cm2/surface 
area: ~ 1-2 weeks). For bioluminescence imaging, in brief, rats were anesthetized by inhalation of 2% 
vol. isoflurane, and injected intraperitoneally with 1.5 mL of 15 mg/mL VivoGlo™ Luciferin (Promega, 
Madison, WI, USA) 10 min prior to imaging with identical system settings. Thereafter, tumor-bearing 
rats were randomly assigned to different treatments groups (n=3-4) and dosed with free cisplatin (5 
mg/kg) or Cis-pARG-HA NPs (at 5 mg/kg dose-equivalent level of platinum) through a single IP 
administration via IP injection or IP nebulization (i.e., PIPAC). Control animals were intraperitoneally 
injected with DPBS [-] alone.   
The PIPAC procedure was performed as described in our previous study 54. Briefly, a 5 mm and an 11 
mm balloon safety trocar (Kii® Fios® First Entry, Applied Medical, Rancho, Santa Margarita, CA, USA) 
were inserted into the abdominal wall of rats (under continuous anesthesia by 4% vol. sevoflurane) 
placed in a supine position and fixed in a stable position at all four extremities. A constant 8 mmHg 
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carbon dioxide-based capnoperitoneum was established and maintained during the whole procedure. 
Next, a 5 mm camera (laparoscope) and a nebulizer (Micropump-MIP®) (Reger Medizintechnik, 
Rottweil, Germany) were introduced to the 5 mm and 11 mm balloon trocars, respectively. The nebulizer 
was connected to an intravenous high pressure injector using a high pressure line and its nozzle orifice 
was secured just inside the peritoneal cavity. Thereafter, the high pressure injector was activated and a 
pressurized aerosol containing either free cisplatin of Cis-pARG-HA NPs in saline was applied to the 
peritoneal cavity at a flow rate of 0.5 mL/s and a maximal upstream pressure of 20 bars. The constant 
capnoperitoneum of 8 mmHg was maintained for 30 min, and afterwards the aerosol was evacuated via 
a Closed Aerosol Waste system (CAWS). Finally, the trocars were retracted and the PIPAC procedure 
was terminated by suturing the laparoscopic incisions (Coated 4-0 VICRYLTM Plus ETHICON®, 
Johnson and Johnson International, Diegem, Belgium) and intramuscular administration of an analgesic 
(Ketoprofen, Sanofi, Diegem, Belgium). 
To evaluate the antitumor activity of each IP therapeutic approach, tumor growth and progression of 
metastasis were monitored via serial bioluminescence imaging for 3 weeks post-treatment. During the 
study period, animals were observed every 2 days for weight change and signs of pain. Rats showing 
the gross sign of toxicity, >20% loss in the body weight or bloated abdomen, were euthanized according 
to an approved animal procedure. 21 days after treatments at the latest, the animals were sacrificed and 
all peritoneal nodules and other organs in the peritoneal cavity were carefully examined and excised. 
The extent of tumor dissemination, weight of tumor nodules and overall survival were subsequently 
recorded for each treatment group. Upon completion of in vivo imaging, the intensity of 
bioluminescence signals emanating from tumor growth were quantified by Living Image Software. 
Tumor growth was determined by comparing the changes in bioluminescence signal intensities to the 
baseline. These changes were quantified via gating on the area of tumor growth in the peritoneal cavity 
and measured by an average photon flux in radians (photons/s/cm2/surface area), which eventually 
allowed normalization of different signal intensities between rats in all treatments groups and also in the 
same rat over time.  
 
4.12 In vivo biodistribution studies   
SKOV-3 Luc IP2 cells (18 × 106 cells suspended in 5 mL DPBS [-]) were IP injected into athymic 
female nude rats (8-10 weeks old, ≥ 200 g) and allowed to grow until the bioluminescence signal 
intensity from tumor growth reached 1 × 108 radians (photons/sec/cm2/surface area: ~ 1-2 weeks). 
Afterwards, rats bearing IP disseminated tumors were randomly divided into 2 groups (n=3) which 
received IP administration of F-pARG-HA NPs (5 × 109 nanoparticles/rat) either via injection (5 mL) 
or nebulization (10 mL, resulting in the peritoneal administration of 5 ml when taking into account the 
dead volume). Rats in the control group were intraperitoneally injected with DPBS [-] alone. 48 h post-
IP administration, all animals were sacrificed and peritoneal nodules and other organs were harvested, 
fixed in 4% paraformaldehyde in PBS (pH:7.4), snap-frozen in liquid nitrogen and stored at -80 °C for 
further analysis. Thereafter, all samples were cryosectioned at a thickness of 10 µm and cryosections 
were equilibrated at RT, washed with DPBS[-] and nuclei of cells were counterstained with Hoechst 
33342 (10 µg/mL). The stained tissue sections were subsequently assessed by fluorescence confocal 
microscopy (C2 Nikon) and images were processed and analyzed by Image J. 
 
4.13 Statistical analysis 
Results were analyzed using GraphPad Prism 7 software and statistical comparisons were conducted 
with one-way or two-way ANOVA. A P-value < 0.05 was considered statistically significant. Data were 
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